ACAD - ACADIA Pharmaceuticals Inc.
| Previous Close | 25.66 |
| Open | 25.34 |
| Bid | 24.97 x 800 |
| Ask | 25.05 x 1400 |
| Day's Range | 24.93 - 25.72 |
| 52 Week Range | 12.77 - 28.67 |
| Volume | 808,284 |
| Avg. Volume | 1,338,314 |
| Market Cap | 3.608B |
| Beta (3Y Monthly) | 2.34 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.10 |
| Earnings Date | Aug 6, 2019 - Aug 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 32.55 |
- Business Wire•yesterday
ACADIA Pharmaceuticals to Present Phase 2 CLARITY Results for Pimavanserin as an Adjunctive Treatment in Major Depressive Disorder at the 2019 American Psychiatric Association Annual Meeting
ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced it will present data from its Phase 2 CLARITY study, which evaluated the efficacy, safety, and tolerability of pimavanserin as an adjunctive treatment for major depressive disorder at the ...
- Thomson Reuters StreetEvents•10 days ago
Edited Transcript of ACAD earnings conference call or presentation 1-May-19 8:30pm GMT
Q1 2019 ACADIA Pharmaceuticals Inc Earnings Call
- Motley Fool•11 days ago
Why Acadia Pharmaceuticals Stock Slumped in April
The contentious drug-pricing debate weighed on Acadia Pharmaceuticals' shares last month.
- Business Wire•12 days ago
ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2019
ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Bank of America Merrill Lynch Health Care Conference 2019 on Tuesday, May 14, 2019 at 10:40 a.m.
- Markit•12 days ago
See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc NASDAQ/NGS:ACADView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is moderate for ACAD with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding ACAD are favorable, with net inflows of $2.89 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Motley Fool•17 days agoAcadia Pharmaceuticals (ACAD) Q1 2019 Earnings Call Transcript
ACAD earnings call for the period ending March 31, 2019.
- Zacks•18 days ago
Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Tops Revenue Estimates
Acadia (ACAD) delivered earnings and revenue surprises of -9.26% and 6.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•18 days ago
Acadia: 1Q Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of 59 cents. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
- Business Wire•18 days ago
ACADIA Pharmaceuticals Reports First Quarter 2019 Financial Results
- 1Q19 Net Sales Grew to $63.0 Million, a 29% Increase Over 1Q18- Updated 2019 Net Sales Guidance to $280 Million to $300 Million- Completed Enrollment in Two Late-Stage Adjunctive
- Insider Monkey•20 days ago
Were Hedge Funds Right About Flocking Into ACADIA Pharmaceuticals Inc. (ACAD)?
Is ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably but historically their consensus stock […]
- American City Business Journals•23 days ago
Analysts point to potential Biogen M&A options after Alzheimer's failure
Is Biogen continuing to strike out? Coming off the company's first earnings call since its lead Alzheimer's disease drug failed, some analysts think so.
- Business Wire•24 days ago
ACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program with Pimavanserin as Adjunctive Treatment for Major Depressive Disorder
ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced the initiation of the Phase 3 CLARITY-2 study and plans to initiate the Phase 3 CLARITY-3 study in the upcoming months.
- Zacks•25 days ago
Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.•last month
Should ACADIA Pharmaceuticals (NASDAQ:ACAD) Be Disappointed With Their -30% Profit?
While it may not be enough for some shareholders, we think it is good to see the ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) share price up 12% in a single quarter. But that doesn't change the fact that the returns over the last...
- Business Wire•last month
ACADIA Pharmaceuticals to Announce First Quarter 2019 Financial Results on May 1, 2019
ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its financial results for the first quarter ended March 31, 2019 on Wednesday, May 1, 2019, after the U.S. financial markets close. ACADIA’s management will host a conference call and webcast on Wednesday, May 1, 2019, at 4:30 p.m. Eastern Time to discuss ACADIA’s financial results and operations. The conference call may be accessed by dialing 855-638-4820 for participants in the United States or Canada and 443-877-4067 for international callers (reference passcode 6759227).
- Business Wire•last month
ACADIA Pharmaceuticals Supports Parkinson’s Disease Awareness Month and World Parkinson’s Day with Local Educational Initiatives and Community Events Across the Country
ACADIA is committed to supporting the Parkinson’s community and increasing awareness about Parkinson’s disease (PD) and Parkinson’s disease psychosis (PDP), a progressive and debilitating non-motor condition characterized by hallucinations and delusions related to PD. “We are driven to improve the lives of people with Parkinson’s disease psychosis and their caregivers,” said Steve Davis, ACADIA’s Chief Executive Officer.
- Business Wire•2 months ago
ACADIA Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference on April 9, 2019
ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 18th Annual Needham Healthcare Conference on Tuesday, April 9, 2019 at 11:20 a.m.
- Business Wire•2 months ago
ACADIA Pharmaceuticals Announces Promotion of Elena Ridloff, CFA to Executive Vice President, Chief Financial Officer
ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced the promotion of Elena Ridloff, CFA to Executive Vice President, Chief Financial Officer.
- GlobeNewswire•2 months ago
Analysis: Positioning to Benefit within American Water Works, TripAdvisor, ACADIA Pharmaceuticals, Dril-Quip, Domtar, and Cara Therapeutics — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, March 29, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Benzinga•2 months ago
The Daily Biotech Pulse: Blueprint Medicine Expedites Clinical Programs, Eyepoint Offering, Precision Biosciences IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 27) Baxter International Inc (NYSE: BAX ) Catalyst Pharmaceuticals ...
- Business Wire•2 months ago
Positive Phase 2 Study Results of Trofinetide in Pediatric Rett Syndrome Published in Neurology, the Medical Journal of the American Academy of Neurology
ACADIA Pharmaceuticals Inc. (ACAD), Neuren Pharmaceuticals Limited (NEU.AX), and Rettsyndrome.org (RSO) announced today that the positive results from a Phase 2 study conducted by Neuren, which evaluated the safety and efficacy of trofinetide in females with Rett syndrome (RTT), have been published in Neurology®, the medical journal of the American Academy of Neurology.
- CNW Group•2 months ago
HLS Therapeutics Announces Q4 and Year-End 2018 Financial Results
HLS Therapeutics Announces Q4 and Year-End 2018 Financial Results
